CADLEarnings•globenewswire•
Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Sentiment:Negative (10)
Summary
NEEDHAM, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today financial results for the second quarter ended June 30, 2025, and provided a corporate update.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 14, 2025 by globenewswire